Source: GlobalData
Bladder cancer diagnosed incident cases across 8MM to reach 0.34 million in 2033, forecasts GlobalData
Posted in Pharma
The diagnosed incident cases of bladder cancer in the eight major markets (8MM*) are set to register an annual growth rate (AGR) of 2.24% from 0.28 million in 2023 to 0.34 million in 2033, forecasts GlobalData, a leading data and analytics company.
GlobalData’s latest report, “Bladder Cancer – Epidemiology Forecast to 2033,” reveals that the US will have the highest number of diagnosed incident cases of bladder cancer among the 8MM at 0.10 million cases, whereas France will have the lowest number at 0.02 million cases in 2033.
Antara Bhattacharya, Associate Project Manager, Epidemiology team at GlobalData, comments: “In 2023, men are more affected than women with approximately 78% men and 22% women.”
Older adults in ages 60 years and above accounted for almost 87% of the diagnosed incident cases of bladder cancer in the 8MM in 2023, while younger adults in ages 18–59 years accounted for approximately 13% of the cases.
GlobalData estimates that in 2023, approximately 45% of the incident cases of bladder cancer were diagnosed in the early stages by AJCC TNM staging, whereas only 6% of cases had a delayed diagnosis. Additionally, approximately 79% of the incident cases by tumor “T” stage at diagnosis were diagnosed in earlier stages, whereas only 4% cases were in severe stages.
The high rate of diagnosis at earlier stages can be attributed to the success of increasing rates of cystoscopy, which is an invasive and expensive procedure. Approximately 74% of diagnosed prevalent cases of NMIBC relapse or recurred to MIBC.
Bhattacharya concludes: “Bladder cancer is the ninth most common cancer type, and timely detection of the disease is both challenging and expensive. Diagnosis relies mainly on cystoscopy, which is an invasive procedure and difficult in low-resource settings. Even after being diagnosed in early stages when the disease is highly treatable, the relapse and recurrence rates are high.
“Hence, adequate research and medical interventions are needed to facilitate different medical approaches for the timely detection and treatment. Epidemiological studies focusing on bladder cancer stages with relapse or recurrence can improve treatment outcomes. Additionally, bladder cancer treatment requires a multifaceted approach that integrates medical and surgical interventions, lifestyle modifications, ongoing support, along with immunotherapy, targeted therapy, clinical trials, and follow-up care.”
*8MM: The US, 5EU (France, Germany, Italy, Spain, the UK), Japan, and urban China.